TELA Bio (TELA)
(Delayed Data from NSDQ)
$3.00 USD
+0.04 (1.35%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $2.99 -0.01 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
TELA Bio, Inc. (TELA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.80 | $14.00 | $8.00 | 264.86% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for TELA Bio, Inc. comes to $10.80. The forecasts range from a low of $8.00 to a high of $14.00. The average price target represents an increase of 264.86% from the last closing price of $2.96.
Analyst Price Targets (5 )
Broker Rating
TELA Bio, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TELA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Lake Street Capital Markets | Frank Takkinen | Strong Buy | Strong Buy |
8/13/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
8/13/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
5/21/2024 | Canaccord Genuity | Caitlin Cronin | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $10.80 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.37 |